

Resource Summary Report

Generated by [RRID](#) on Aug 7, 2026

E.G7-OVA

RRID:CVCL_3505

Type: Cell Line

Proper Citation

BCRC Cat# 60418, RRID:CVCL_3505

Cell Line Information

URL: https://web.expasy.org/cellosaurus/CVCL_3505

Proper Citation: BCRC Cat# 60418, RRID:CVCL_3505

Description: Cell line E.G7-OVA is a Cancer cell line with a species of origin Mus musculus (Mouse)

Sex: Sex unspecified

Disease: Mouse precursor T cell lymphoblastic lymphoma/leukemia

Defining Citation: [PMID:3261634](#)

Category: Cancer cell line

Organism: Mus musculus (Mouse)

Name: E.G7-OVA

Synonyms: E.G7-Ova

Cross References: CLO:CLO_0002854, ATCC:CRL-2113, BCRC:60418, Wikidata:Q54831634

ID: CVCL_3505

Vendor: BCRC

Catalog Number: 60418

Hierarchy: cvcl_0255

Record Creation Time: 20250130T071113+0000

Record Last Update: 20260802T005254+0000

Ratings and Alerts

No rating or validation information has been found for E.G7-OVA.

No alerts have been found for E.G7-OVA.

Data and Source Information

Source: [CelloSaurus](#)

Usage and Citation Metrics

We found 38 mentions in open access literature.

Listed below are recent publications. The full list is available at [RRID](#) .

Kelly B, et al. (2026) Distinct control of T cell proliferation and effector function by partitioning of intracellular sulfur from cysteine. *bioRxiv : the preprint server for biology*.

Philbrook P, et al. (2026) Medium-Chain Fatty Acid Receptor GPR84 Modulates Cytotoxic CD8 T-cell Antitumor Immunity through Metabolic Reprogramming. *Cancer immunology research*, 14(4), 640.

Fischer TD, et al. (2026) Intratumoral Virus-Like Particles Containing a TLR9 Agonist Combined with Systemic ?PD-1 Activate Tumor-Specific CD8+ T Cells. *Cancer research communications*, 6(5), 1006.

Kelly B, et al. (2026) Sulfur partitioning from cysteine controls T cell proliferation and effector function. *Cell*, 189(12), 3669.

Liu Y, et al. (2026) Immunogenic tumor cell death and T-cell-derived IFN-? elicit tumoricidal macrophages to potentiate OX40 immunotherapy. *Cell reports. Medicine*, 7(4), 102699.

Miller ML, et al. (2026) Fungal-derived cellobiose metabolic pathway fuels T cells to bypass intratumoral glucose competition. *Cell*, 189(6), 1717.

Fournier C, et al. (2025) Nanostructured lipid carriers based mRNA vaccine leads to a T cell-inflamed tumour microenvironment favourable for improving PD-1/PD-L1 blocking therapy and long-term immunity in a cold tumour model. *EBioMedicine*, 112, 105543.

Perez-Quintero LA, et al. (2025) Uncovering the individual immunotherapeutic roles of PTPN1 and PTPN2 in T cells during dual inhibition. *iScience*, 28(10), 113610.

Bikorimana JP, et al. (2025) Forced intracellular degradation of xenoantigens as a modality for cell-based cancer immunotherapy. *iScience*, 28(3), 111957.

Ding R, et al. (2024) Lactate modulates RNA splicing to promote CTLA-4 expression in tumor-infiltrating regulatory T cells. *Immunity*, 57(3), 528.

Wakamatsu E, et al. (2024) Indirect suppression of CD4 T cell activation through LAG-3-mediated trans-endocytosis of MHC class II. *Cell reports*, 43(9), 114655.

Gonçalves MP, et al. (2024) A1-reprogrammed mesenchymal stromal cells prime potent antitumoral responses. *iScience*, 27(3), 109248.

Kim HY, et al. (2024) Specific targeting of cancer vaccines to antigen-presenting cells via an endogenous TLR2/6 ligand derived from cysteinyl-tRNA synthetase 1. *Molecular therapy : the journal of the American Society of Gene Therapy*, 32(10), 3597.

Hao J, et al. (2024) NR4A1 transcriptionally regulates the differentiation of stem-like CD8+ T cells in the tumor microenvironment. *Cell reports*, 43(6), 114301.

Kamei M, et al. (2024) Intratumoral delivery of a highly active form of XCL1 enhances antitumor CTL responses through recruitment of CXCL9-expressing conventional type-1 dendritic cells. *International journal of cancer*.

Zhou W, et al. (2024) Stem-like progenitor and terminally differentiated TFH-like CD4+ T cell exhaustion in the tumor microenvironment. *Cell reports*, 43(2), 113797.

Hung YP, et al. (2024) Enhanced tumor control activities of anti-mPD-L1 antibody and antigen-presenting cell-like natural killer cell in an allograft model. *BMC cancer*, 24(1), 136.

Hernandez-Franco JF, et al. (2024) Intradermal vaccination with a phytoglycogen nanoparticle and STING agonist induces cytotoxic T lymphocyte-mediated antitumor immunity. *NPJ vaccines*, 9(1), 149.

Nishi W, et al. (2023) Evaluation of therapeutic PD-1 antibodies by an advanced single-molecule imaging system detecting human PD-1 microclusters. *Nature communications*, 14(1), 3157.

Lazear MR, et al. (2023) Proteomic discovery of chemical probes that perturb protein complexes in human cells. *Molecular cell*, 83(10), 1725.